Suchergebnisse - Laurence Albigès

Treffer weiter einschränken
  1. 1
    Nivolumab in renal cell carcinoma: latest evidence and clinical potential

    Nivolumab in renal cell carcinoma: latest evidence and clinical potential von Camille Mazza, Bernard Escudier, Laurence Albigès

    Veröffentlicht 2016
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma von Elie Rassy, Ronan Flippot, Laurence Albigès

    Veröffentlicht 2020
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  3. 3
    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer von Karim Fizazi, Laurence Albigès, Yohann Loriot, Christophe Massard

    Veröffentlicht 2015
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma

    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma von Hassan Izzedine, Lisa Derosa, Gwénaël Le Teuff, Laurence Albigès, Bernard Escudier

    Veröffentlicht 2015
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases

    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases von Laurence Albigès, Fabrice André, Corinne Balleyguier, Gonzalo Gomez-Abuin, Agnès Chompret, Suzette Delaloge

    Veröffentlicht 2005
    Volltext Volltext
    Carta
    Zu den Favoriten
    Gespeichert in:
  6. 6
    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma

    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma von Laurence Albigès, Philippe Barthélémy, Marine Gross‐Goupil, Sylvie Négrier, Michael N. Needle, Bernard Escudier

    Veröffentlicht 2020
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma von Laurence Albigès, Foucauld Chamming’s, Brigitte Duclos, M. Stern, Robert J. Motzer, Alain Ravaud, P. Camus

    Veröffentlicht 2012
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography von Nathalie Lassau, Serge Koscielny, Laurence Albigès, L. Chami, Baya Benatsou, Mohamed Chébil, Alain Roche, Bernard Escudier

    Veröffentlicht 2010
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma

    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma von Christophe Maritaz, David Combarel, Cécile Dalban, Louis Blondel, Sophie Broutin, Aurélien Marabelle, Laurence Albigès, Angélo Paci

    Veröffentlicht 2025
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events von Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albigès, Rachel H. Giles, Eric Jonasch

    Veröffentlicht 2020
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  11. 11
    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients von Luc Cabel, Elika Loir, Gwénaëlle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albigès, Giulia Baciarello, Yohann Loriot, Karim Fizazi

    Veröffentlicht 2017
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma von Guillermo de Velasco, Katherine M. Krajewski, Laurence Albigès, Mark M. Awad, Joaquim Bellmunt, F. Stephen Hodi, Toni K. Choueiri

    Veröffentlicht 2015
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma von Thomas Powles, Laurence Albigès, Axel Bex, Viktor Grünwald, Camillo Porta, Giuseppe Procopio, Manuela Schmidinger, Cristina Suárez, Guillermo de Velasco

    Veröffentlicht 2021
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  14. 14
    Who dies from prostate cancer?

    Who dies from prostate cancer? von Anna Patrikidou, Yohann Loriot, J-C Eymard, Laurence Albigès, Christophe Massard, E. Ileana, Mario Di Palma, Bernard Escudier, Karim Fizazi

    Veröffentlicht 2014
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Renal cell carcinoma

    Renal cell carcinoma von James J. Hsieh, Mark P. Purdue, Sabina Signoretti, Charles Swanton, Laurence Albigès, Manuela Schmidinger, Daniel Y.C. Heng, James Larkin, Vincenzo Ficarra

    Veröffentlicht 2017
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  16. 16
    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) von Yohann Loriot, Diletta Bianchini, E. Ileana, Shahneen Sandhu, Anna Patrikidou, Carmel Pezaro, Laurence Albigès, Gerhardt Attard, Karim Fizazi, Johann S. de Bono, Christophe Massard

    Veröffentlicht 2013
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience

    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience von Baptiste Bonnet, Louis Tournier, Frédèric Deschamps, Steven Yevich, Aurélien Marabelle, Caroline Robert, Laurence Albigès, Benjamin Besse, V Bonnet, Thierry de Baère, Lambros Tselikas

    Veröffentlicht 2024
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma von Anthony Saroufim, Yosra Messai, Meriem Hasmim, Nathalie Rioux, Roberto Iacovelli, G. Verhoest, Karim Bensalah, J-J Patard, Laurence Albigès, Bruno Azzarone, Bernard Escudier, Salem Chouaı̈b

    Veröffentlicht 2014
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Chk1 as a new therapeutic target in triple-negative breast cancer

    Chk1 as a new therapeutic target in triple-negative breast cancer von Laurence Albigès, Aïcha Goubar, Véronique Scott, Cécile Vicier, Céline Lefèbvre, Samar Alsafadi, Frédéric Commo, Mahasti Saghatchian, Vladimir Lazar, Philippe Dessen, Suzette Delaloge, Fabrice André, Virginie Quidville

    Veröffentlicht 2014
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors

    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors von Sarah C. Markt, Carlos Lago‐Hernandez, Rowan Miller, Brandon A. Mahal, Brandon Bernard, Laurence Albigès, Lindsay A. Frazier, Clair J. Beard, Alexi A. Wright, Christopher J. Sweeney

    Veröffentlicht 2016
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: